It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Evaluation of scar severity is crucial for determining proper treatment modalities; however, there is no gold standard for assessing scars. This study aimed to develop and evaluate an artificial intelligence model using images and clinical data to predict the severity of postoperative scars. Deep neural network models were trained and validated using images and clinical data from 1283 patients (main dataset: 1043; external dataset: 240) with post-thyroidectomy scars. Additionally, the performance of the model was tested against 16 dermatologists. In the internal test set, the area under the receiver operating characteristic curve (ROC-AUC) of the image-based model was 0.931 (95% confidence interval 0.910‒0.949), which increased to 0.938 (0.916‒0.955) when combined with clinical data. In the external test set, the ROC-AUC of the image-based and combined prediction models were 0.896 (0.874‒0.916) and 0.912 (0.892‒0.932), respectively. In addition, the performance of the tested algorithm with images from the internal test set was comparable with that of 16 dermatologists. This study revealed that a deep neural network model derived from image and clinical data could predict the severity of postoperative scars. The proposed model may be utilized in clinical practice for scar management, especially for determining severity and treatment initiation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Yonsei University College of Medicine, Department of Dermatology, Yongin Severance Hospital, Yongin-si, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University College of Medicine, Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
2 LG Chem Ltd., Seoul, South Korea (GRID:grid.464630.3) (ISNI:0000 0001 0696 9566)
3 Yonsei University College of Medicine, Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
4 Yonsei University College of Medicine, Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University College of Medicine, Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)